Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Rhinomed Limited
  6. News
  7. Summary
    RNO   AU000000RNO1


End-of-day quote. End-of-day quote Australian Stock Exchange - 11/29
0.255 AUD   -5.56%
11/18RHINOMED : CEO presentation to 2021 AGM
11/10Investor update November 2021
10/26Rhinomed Secures Ethics Approval for Post-Market Trial of Nasal Swab Product
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news


10/19/2021 | 03:01am EST

DGAP-News: Rhinomed Limited / Key word(s): Miscellaneous NEW SWAB TAKES AWAY CHILDREN'S FEAR OF SWABBING 2021-10-19 / 09:00 The issuer is solely responsible for the content of this announcement.


- Rhinoswab Junior^TM is the world's first nasal swab designed specifically to reduce the distress and discomfort children experience during COVID-19 testing

- Rhinoswab Junior^TM is a high yield, cost effective swab that can be comfortably self-administered by children

- Rhinoswab can be used to sample for COVID-19 and other respiratory diseases, with PCR and rapid antigen tests

- Rhinomed is seeking further European product distributors

19 October 2021: Rhinomed Limited (ASX:RNO OTCQB:RHNMF), a leader in wearable nasal and respiratory technology, has developed Rhinoswab Junior^TM to reduce the fear and anxiety associated with existing standard throat and deep nasal swabs and encourage greater testing of children for COVID-19, including the growing use of rapid antigen tests in schools and homes.

The need for a less invasive and more comfortable approach is supported by a poll conducted by Melbourne's Royal Children's Hospital^[1] (RCH) which found that 74% of parents were likely to avoid having their children tested due to fears that a COVID-19 test would be stressful, painful or uncomfortable their child.

Rhinoswab Junior^TM is based on Rhinomed's proven, innovative Rhinoswab^TM which enables accurate, safer, comfortable and less invasive self-administered sampling, and has FDA, European CE Mark and Australian TGA registration. Rhinoswab^TM has flocked swabs that are applied to both nostrils in a fixed position. It works with existing PCR and antigen tests and is equivalent in cost to US and European swabs.

Results from a recent comparison study of Rhinoswab versus the standard swab (n= 302) at CWZ and Radboud University Medical Center, a leading teaching hospital in the Netherlands, showed that;

- 87% of participants preferred Rhinoswab to the nasopharyngeal swab

- 98% of participants felt no pain with Rhinoswab vs 48% with nasopharyngeal swab

- 98% of participants needed little or no guidance when using Rhinoswab.

Rhinomed Junior^TM is a smaller version of the Rhinoswab^TM with child friendly features to engage children in the sampling process including fun additions like mustaches, lips and animal faces.

Rhinomed CEO Michael Johnson commented, "Testing rates in children remain low due in part to the anxiety and distress children can experience when being tested with a standard swab. We have sought to develop a swab that not only works better, but is easy and even fun to use - not just for the children but their parents and healthcare workers.

Rhinoswab Junior^TM will make repeat rapid antigen testing at schools, homes and other venues easier and more comfortable for children."

Rhinomed has appointed BioTrading Benelux BV as its Rhinoswab(TM) distributor in Belgium, the Netherlands and Luxembourg (Benelux) and is seeking further distributors and commercial partners including rapid antigen testing companies.

For more information visit https://www.rhinomed.global/about-rhino-med/sample-collection/rhinoswab-junior/

Company                            Investor and Media Relations 
Michael Johnson,                   Rudi Michelson 
CEO & Director                     Monsoon Communications 
+61 (0) 3 8416 0900                +61(0) 411 402 737 
mjohnson@rhinomed.global           rudim@monsoon.com.au 
Follow us on Twitter @rhinomedceo 

^[1] https://www.rchpoll.org.au/polls/covid-19-testing-in-kids-what-concerns-parents


2021-10-19 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de


Language:     English 
Company:      Rhinomed Limited 
              97 Green Street 
              3121 Cremone 
Internet:     https://www.rhinomed.global/ 
EQS News ID:  1241583 
End of News   DGAP News Service 

1241583 2021-10-19

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=26213a242d18d69339246ab65213429c

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1241583&application_name=news

(END) Dow Jones Newswires

October 19, 2021 03:00 ET (07:00 GMT)

11/18RHINOMED : CEO presentation to 2021 AGM
11/10Investor update November 2021
10/26Rhinomed Secures Ethics Approval for Post-Market Trial of Nasal Swab Product
10/26Rhinoswab Clinical Trial Approves At St Vincent's Hospital
10/19RHINOMED : New swab takes away children's fear of swabbing
09/28Rhinomed Limited Auditor Raises 'Going Concern' Doubt
09/13Rhinomed Limited Appoints Rhinoswab Distributors for Australia and Belgium, the Netherl..
09/10RHINOMED : to Deliver One Million COVID-19 Nasal Swabs to Australia's Victoria Government
09/09Rhinomed Limited Receives an Initial Purchase Order for One Million Rhinoswabs from the..
08/26Rhinomed Limited Announces Ethics Approval Granted for Clinical Trial of First Nasal Sw..
More news
Sales 2021 4,42 M 3,16 M 3,16 M
Net income 2021 -8,64 M -6,17 M -6,17 M
Net cash 2021 1,87 M 1,34 M 1,34 M
P/E ratio 2021 -4,55x
Yield 2021 -
Capitalization 64,7 M 46,1 M 46,2 M
EV / Sales 2020 2,37x
EV / Sales 2021 8,48x
Nbr of Employees -
Free-Float 10,1%
Duration : Period :
Rhinomed Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RHINOMED LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Managers and Directors
Michael Johnson Chief Executive Officer, MD & Executive Director
Sean Slattery Chief Financial Officer & Secretary
Ronald R. Dewhurst Non-Executive Chairman
Brent J. Scrimshaw Independent Non-Executive Director
Eric Knight Independent Non-Executive Director
Sector and Competitors